# Quant Analyst

- Symbol: MCHP
- Elapsed: 42.1s

---
# MCHP — Quantitative Factor Report

**Microchip Technology (NASDAQ: MCHP)** · Technology / Semiconductors · Price $58.35 · Mkt Cap $31.7B · FY-end 2026-03-31

---

## 1. Factor Scores

Sector ranks are computed against the closest **analog/MCU peer set: TXN, ADI, NXPI, ON, MCHP** (n=5). This is an intentionally narrow comp group — the "Technology sector" list returned by the screener is dominated by mega-cap software/NVDA-type names that are not valid factor comparables for a cyclical analog semi.

| Factor | Score | Sector Rank (of 5) | Signal |
|--------|-------|--------------------|--------|
| **Value** | P/E 224.4x · EV/EBITDA 26.6x · P/FCF 36.7x · P/B 4.97x | **3rd** (~60th pct) | **Neutral** |
| **Momentum** | +1.33% (12-1) · +3.34% (6-1) | **3rd** (~60th pct) | **Neutral / mildly positive** |
| **Quality** | ROE 3.14% · GP/A 0.189 · Accruals −5.29% | **4th–5th** (~bottom quintile) | **Negative** |
| **Low Vol** | Vol 53.6% · Beta 2.25 · MaxDD −42.9% | **4th** (~bottom quintile) | **Negative** |
| **Earnings Revision** | +13.87% vs 3 months prior | Peer: TXN +36.9%, NXPI +1.8% | **Positive** (caveat below) |

**Factor detail and rankings:**

- **Value (rank 3/5):** On EV/EBITDA MCHP is genuinely cheap — 26.6x ranks 2nd behind only NXPI (18.9x). But the 224x P/E is a trough-earnings artifact, not value: net income is $202M versus $2.24B in FY2023. Averaging rank across P/E (5th), EV/EBITDA (2nd), P/FCF (3rd) puts MCHP mid-pack. **TXN ranks cheapest-negative on P/FCF (97.3x) and ADI on EV/EBITDA (36.9x) — MCHP is the better value of the two on cash-flow multiples.**
- **Momentum (rank 3/5):** ADI +11.1% leads, TXN +2.3%, MCHP +1.3%, NXPI −6.8%, ON −7.4%. MCHP is modestly positive and improving (6-1 momentum +3.3% ≈ 12-1 +1.3%), so no short-term reversal evidence, but no leadership either.
- **Quality (rank 4–5):** ROE of 3.14% is 4th of 5; GP/A of 0.189 is 3rd (ahead of ON and ADI); accruals of −5.29% are clean but only 4th. **The one genuinely high-quality read: accruals have been negative every year for four straight years (−5.29%, −5.84%, −6.21%, −8.45%) — cash conversion is consistently better than reported earnings, i.e. earnings are *not* accrual-inflated.** Piotroski F-Score = **6/9 (Moderate)**, with points lost on leverage (F5), negative equity change (F6), and share dilution (F7).
- **Low Vol (rank 4/5):** Bottom quintile on all three sub-measures — vol 4th, beta 4th, drawdown 4th. Only ON is worse.
- **Earnings Revision:** +13.87% is the strongest single factor score. **Caveat: the tool compared the 2029-03-31 forward period, not a next-12-month estimate** — it is measuring long-dated estimate drift, not near-term revision breadth. Peer comparison floats the same caveat (TXN's is 2030-12-31). Treat as a directional positive only.

---

## 2. Price Statistics

| Metric | 1-Year (252d) | 3-Year (756d) |
|---|---|---|
| Annualised return | **−15.71%** | +4.24% |
| Annualised volatility | 54.1% | 54.8% |
| **Alpha vs SPY (annualised)** | **−40.11%** | **−28.48%** |
| **Beta vs SPY** | **2.27** | **2.14** |
| R² vs SPY | 0.359 | 0.418 |
| **Sharpe (0% rf)** | **−0.29** | **+0.08** |
| **Sortino (0% rf)** | **−0.439** | **+0.115** |
| **Max drawdown** | **−42.85%** | — |
| Company-reported beta (5y) | 1.85 | — |

**Interpretation:** Beta is stable at ~2.1–2.3x across both windows, so the high-beta profile is structural, not a one-year artifact. Alpha is deeply negative and *persistent* (−40.1% 1y, −28.5% 3y) — this is not noise, it is two consecutive years of severe underperformance versus the benchmark. R² of only 0.36–0.42 means ~60% of MCHP's variance is idiosyncratic, so single-name/cycle risk dominates market risk. Sortino below Sharpe (both windows) confirms downside volatility is larger than upside volatility — a bad asymmetry.

**Peer risk-adjusted comparison (1y Sharpe):** TXN **0.98** > ADI 0.74 > NXPI 0.51 > ON 0.46 > **MCHP −0.29**. MCHP is the *only* name in the comp group with a negative Sharpe. It has the 2nd-highest beta (2.25) and the 2nd-deepest drawdown in the group.

**Peer correlation (1y):** MCHP–ADI 0.81, MCHP–TXN 0.80, MCHP–ON 0.76, MCHP–NXPI 0.73, MCHP–SPY 0.60. Tight cluster with analog peers — **effectively no diversification benefit versus TXN/ADI/ON exposure**; MCHP is a high-beta expression of the identical analog-cycle factor.

---

## 3. Composite Quant Signal: **NEUTRAL (with a sell bias on risk-adjusted terms)**

| Factor | Direction | Weight | Contribution |
|---|---|---|---|
| Value | Neutral (cheap on EV/EBITDA, distorted P/E) | 25% | 0 |
| Momentum | Mildly positive | 20% | + |
| Quality | Negative | 25% | − |
| Low Vol | Negative | 15% | − |
| Earnings Revision | Positive (long-dated caveat) | 15% | + |

The factors genuinely cancel. **Value and revision momentum say "cycle trough, estimates inflecting."** Quality and low-vol say "worst risk-adjusted profile in the peer group, and you are paying 2.25 beta for it." There is no top-quintile score on any factor — no combination here meets the bar for a high-conviction long.

**The bull case is a mean-reversion/turn thesis:** ROIC of 4.1% versus 20.3% in FY2024 and 23.8% in FY2023 shows the business is deep in a cyclical trough, and accruals are clean. If the cycle inflects, EV/EBITDA of 26.6x compresses rapidly on recovering EBITDA and the +13.9% estimate revision is the leading indicator. **That is a qualitative cycle call, not a quantitative signal** — the quant data does not yet confirm it: momentum is only +1.3%, and the stock has failed to convert clean earnings into shareholder return (F-Score 6, lost points on dilution).

---

## 4. Key Quant Risk Flags

1. **Momentum reversal risk — LOW.** 6-1 momentum (+3.3%) is not worse than 12-1 (+1.3%), so no classic reversal setup. But the absolute level is negligible; a single quarter's guidance miss on 54% vol moves the stock ±15%+.
2. **Factor crowding — HIGH.** Correlation of 0.73–0.81 with TXN/ADI/ON/NXPI means MCHP offers no diversification value within an analog semi sleeve. It is the *highest-beta* way to own the same factor, which amplifies crowding risk on the downside.
3. **Liquidity — NOT a concern.** $31.7B market cap, 17,900 employees, 548M diluted shares. Institutional-grade liquidity.
4. **Estimate-revision data quality — FLAG.** The revision score compares a **2029-03-31** forward period. This is long-dated drift, not a near-term (NTM) revision signal, and should not be weighted as a standard 3-month revision reading. Peer data has the same defect (2030-12-31).
5. **Earnings-quality/loss-of-scale risk — MEDIUM.** Net income collapsed from $2.24B (FY23) → $1.91B (FY24) → −$0.5M (FY25) → $202M (FY26). Share count rose (dilution, F7 = 0) and book equity fell (F6 = 0). The recovery is early and unproven.
6. **Sample size — ADEQUATE but thin on cross-section.** n=5 peer group is too small for statistically meaningful z-scores or quintile assignment; ranks shown are ordinal and should be read as indicative, not significant. The 3-year alpha/beta regression (R² 0.42) has ~756 observations — that result *is* statistically meaningful and it is persistently negative.

**Bottom line:** Quantitatively this is a **Neutral-to-Sell**: cheap on EV/EBITDA with clean accruals and an inflecting estimate, but bottom-quintile quality, bottom-quintile risk-adjusted returns (negative Sharpe and Sortino), 2.25 beta, −42.9% drawdown, and persistently negative alpha over both 1 and 3 years. The data supports only a cycle-turn bet — not a factor-based buy.
